New combo may boost lung cancer treatment for patients with two gene mutations
NCT ID NCT04695925
First seen Nov 01, 2025 · Last updated Jun 06, 2026 · Updated 28 times
Summary
This study tests whether adding chemotherapy (carboplatin and pemetrexed) to the targeted drug osimertinib works better than osimertinib alone for people with advanced non-squamous lung cancer that has both EGFR and TP53 gene mutations. About 294 adults who have not had prior treatment will be randomly assigned to one of the two groups. The main goal is to see if the combination delays cancer growth longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Central Hospital of Guangdong Nongken, Zhanjiang Cancer Hospital
Zhanjiang, China
-
Department of Medical Oncology,Cancer Center of Sun Yat-Sen University
Guangzhou, Guangdong, 510060, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.